On March 14th, 2023, GSK announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. Invasive meningococcal disease (IMD), a major cause of meningitis and septicaemia, is an uncommon but serious illness that can cause life-threatening complications or even death, typically amongst previously healthy children and adolescents.
The study enrolled 815 participants in Finland in 2020 through FVR – Finnish Vaccine Research (then known as Tampere University’s Vaccine Research Centre). Read the announcement by GSK HERE >>
CHIEF MEDICAL OFFICER
mika.ramet (at) fvr.fi